Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.48 |
| ▸ | BDNF | P23560 | 3/20 | 0.47 |
| ▸ | MDK | P21741 | 3/20 | 0.47 |
| ▸ | PTN | P21246 | 2/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dermatan SCHEMBL16311126 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL13472480 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL12691925 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL18232151 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL19846466 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| Dermatan SCHEMBL19184706 | 1.00 | LGALS3 (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL24844372 | 0.98 | BDNF (0.50) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL14497205 | 0.98 | BDNF (0.50) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL25785578 | 0.98 | BDNF (0.50) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK | |
| SCHEMBL19295777 | 0.96 | BDNF (0.49) | LGALS3LGALS7; LGALS7BLGALS1BDNFMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3352736-B1 | HYDROPHILIC GEL FOR TOPICAL DELIVERY OF 5-AMINOLEVULINIC ACID | ZIMMER RODEN BIOTECH (DE) | 2026-05-27 | — | — | EP | claimed |
| US-20260131042-A1 | PACKAGING SOLUTIONS | BAUSCH LOMB IRELAND LTD (IE) | 2026-05-14 | — | — | US | claimed |
| EP-4739338-A1 | FUNCTIONALIZED DISACCHARIDASE COMPOSITIONS | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | claimed |
| EP-4739337-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS COMPRISING PANCREATIC ENZYMES | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | claimed |
| US-12599561-B2 | Localized immunosuppression of allografts for peripheral nerve repair | UNIVERSITY OF WYOMING (US) | 2026-04-14 | — | — | US | claimed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| US-12582742-B2 | Packaging solutions | BAUSCH + LOMB IRELAND LIMITED (IE) | 2026-03-24 | — | — | US | claimed |
| US-12576190-B2 | Tissue repair membrane adapted for adhesion and lubrication, and methods for preparing the same | AXOGEN CORPORATION (US) | 2026-03-17 | — | — | US | claimed |
| EP-4706697-A1 | TISSUE REPAIR MEMBRANE ADAPTED FOR ADHESION AND LUBRICATION, AND METHODS FOR PREPARING THE SAME | AxoGen Corporation (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260054913-A1 | CONTACT LENSES HAVING CATIONIC MONOMERS OR CATIONIC POLYMERS FOR RELEASING COMFORT AGENTS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2026-02-26 | — | — | US | claimed |
| EP-4013465-A1 | TISSUE REPAIR MEMBRANE ADAPTED FOR ADHESION AND LUBRICATION, AND METHODS FOR PREPARING THE SAME | Axogen Corporation (US) | 2022-06-22 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-4010301-A1 | A CARBONATED COMPOSITE | CRH Group Services Limited (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022101384-A1 | SYSTEMS FOR BUCCAL RELEASE OF PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-05-19 | — | — | WO | claimed |
| CN-114432236-A | Fuerkang antibacterial cream and preparation method thereof | 咸阳天禹生物科技有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-109069546-B | Edible bird's nest extract and extraction method | 林家明 | 2022-05-06 | — | — | CN | claimed |
| CN-114401987-A | Binding agents and uses thereof | 詹森药业有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-114324869-A | Joint inspection kit for detecting breast cancer and application thereof | 杭州广科安德生物科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-113025496-B | Fungus for inducing anoectochilus formosanus seeds to germinate into seedlings | 中国医学科学院药用植物研究所 | 2022-03-15 | — | — | CN | claimed |
| EP-3962961-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | Bausch & Lomb Incorporated (US) | 2022-03-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260054913-A1 | CONTACT LENSES HAVING CATIONIC MONOMERS OR CATIONIC POLYMERS FOR RELEASING COMFORT AGENTS | TRPA1, ASIC1, ARGLU1 | LGALS3 2707/4885LGALS7; LGALS7B 2405/4885LGALS1 2135/4885 |
| US-12599561-B2 | Localized immunosuppression of allografts for peripheral nerve repair | CD44, CD47, SDCBP | LGALS3 69/4885LGALS7; LGALS7B 119/4885LGALS1 97/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | LGALS3 1526/4885LGALS7; LGALS7B 1820/4885LGALS1 1151/4885 |
| US-12582742-B2 | Packaging solutions | CD44, DSG1, HPSE | LGALS3 528/4885LGALS7; LGALS7B 860/4885LGALS1 330/4885 |
| US-20260131042-A1 | PACKAGING SOLUTIONS | MUC1, ITGA1, MGAT3 | LGALS3 1032/4885LGALS7; LGALS7B 1806/4885LGALS1 763/4885 |
| US-12576190-B2 | Tissue repair membrane adapted for adhesion and lubrication, and methods for preparing the same | CD44, ALG1, PLOD3 | LGALS3 934/4885LGALS7; LGALS7B 2389/4885LGALS1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.